Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.76 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.76 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.76 |
| ▸ | MAOA | P21397 | 1/20 | 0.76 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.76 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | PNMT | P11086 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levamfetamine SCHEMBL1978104 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL6465998 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Levamfetamine SCHEMBL396231 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL4016537 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL8025793 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL2412146 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL7204032 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL18948 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL41203 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL18949 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3599 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3937879-B1 | PREPARATIONS FOR THE PREVENTION OF CORONAVIRUS INFECTIONS ACQUIRED VIA THE ORAL CAVITY AND PHARYNX | MANGORX IP HOLDINGS LLC (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4198126-B1 | COMPOSITION COMPRISING A DNA-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT INHIBITOR AND 53BP1 INHIBITOR, GENE EDITING METHOD, ENGINEERED CELLS, AND USE OF THE COMPOSITION IN GENE EDITING | SCHUMANN KATHRIN (DE) | 2026-04-15 | — | — | EP | claimed |
| US-12544385-B2 | Combination drug therapies for CNS disorders | JAVED MOHAMMAD (US) | 2026-02-10 | — | — | US | claimed |
| EP-4655449-A2 | PROCESS FOR THE PREPARATION OF AN AFTER-TREATMENT AGENT FOR TEXTILE FIBRES AND ITS USE | Zschimmer & Schwarz Mohsdorf GmbH & Co. KG (DE) | 2025-12-03 | — | — | EP | claimed |
| US-20250352538-A1 | PHARMACEUTICAL RESINATE COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | RHODES PHARMACEUTICALS LP (US) | 2025-11-20 | — | — | US | claimed |
| US-12285488-B2 | Oral dosage form containing theobromine-free cocoa | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2025-04-29 | — | — | US | claimed |
| US-20250120908-A1 | ORAL FILM FORMULATION FOR MODULATING ABSORPTION PROFILE | INTELGENX CORP. (CA) | 2025-04-17 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | Pharmapotheca A Inc. (US) | 2025-01-28 | — | — | US | claimed |
| US-12156937-B2 | Oral film formulation for modulating absorption profile | INTELGENX CORP. (CA) | 2024-12-03 | — | — | US | claimed |
| WO-2000021504-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2000-04-20 | — | — | WO | claimed |
| WO-2000001642-A1 | CHIRAL RECOGNITION POLYMER AND ITS USE TO SEPARATE ENANTIOMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-01-13 | — | — | WO | claimed |
| EP-0935523-A4 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GEN MILLS INC (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| US-5023088-A | Drug delivery dispenser | ALZA CORPORATION (US) | 1991-06-11 | — | — | US | claimed |
| US-4952402-A | EDIBLE TASTE-MASKED DRUGS; MICROMATRIX ACTIVE MATERIAL COATED WITH NONTOXIC POLYMER; LIQUIDS; TABLETS | ELAN CORPORATION, P.L.C. (IE) | 1990-08-28 | — | — | US | claimed |
| US-4734222-A | Composition and method for cleaning soft and hard contact lenses | CIBA-GEIGY CORPORATION (US) | 1988-03-29 | — | — | US | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |
| US-3968245-A | Sympathomimetic topical and percutaneous administration with halogenated promoters | ALZA CORPORATION (US) | 1976-07-06 | — | — | US | claimed |